CEA Antigen (recombinant)

Added to your cart

CEA Antigen (recombinant)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P824-3


Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

CEA was first identified in human colon carcinoma tissue extracts and is known to play a critical role as a ligand in cancer dissemination. Elevated serum CEA is found in 17∼47% of colorectal cancer patients. CEA was originally thought to be a specific marker for colon cancer but levels may also be raised in gastric, pancreatic, lung, breast and medullary thyroid carcinomas, as well as some non-neoplastic conditions such as inflammation, pancreatitis, ulcerative colitis, cirrhosis, COPD, Crohn's disease, hypothyroidism and in smokers. For this reason, it is not useful as a general cancer screening tool, but can be useful in evaluating the response to cancer treatment, to monitor metastasis of colorectal cancer to the liver and to indicate recurrence. Elevated CEA levels should return to normal after successful surgical removal of the tumour and can be used in follow up, especially of colorectal cancers. CEA elevation is known to be affected by multiple factors and it varies inversely with tumor grade; well-differentiated tumours secrete more CEA.


More information



  • Shipping Information
  • Dry Ice
  • Abbreviations
  • CEA
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • 20.4mM sodium phosphate, 1.5mM potassium phosphate buffer containing 0.136M sodium chloride and 2.7mM Potassium chloride, pH7.4
  • Presentation Matrix
  • Clear, colourless solution, single homogeneous batch, 0.2µm filtered, supplied frozen in 20.4nM sodium phosphate, 1.5mM potassium phosphate buffer containing 0.136M sodium chloride and 2.7mM potassium chloride, pH7.4.
  • Purity/grade
  • >96%
  • Source
  • Human Cell Line
  • Molecular weight
  • ~180kDa
  • Uniprot No.
  • Q13984_Human

Technical Documents

Certificates Of Analysis (119.9KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox